

9<sup>th</sup> September, 2022

Dear REMAP-CAP sites,

**RE: REMAP-CAP COVID-19 Antiviral Domain**

We are writing to inform you of a decision that has been made by the REMAP-CAP International Trial Steering Committee (ITSC) to close recruitment to the COVID-19 Antiviral Domain.

The current phase of this domain evaluates ivermectin for the treatment of COVID-19. At the time that this domain was re-opened to evaluate this intervention, there was significant public interest in the use of ivermectin for the treatment of COVID-19, despite evidence supporting its use being derived from low-quality and observational studies. The REMAP-CAP ITSC therefore responded to an identified need for high-quality evidence from randomized clinical trials regarding the safety and efficacy of the use of ivermectin in hospitalized patients with severe COVID-19.

At this time, accumulating evidence from randomized controlled trials in a range of settings<sup>1,2,3</sup> does not support the efficacy of ivermectin for the treatment of COVID-19. When combined with the retraction of several high-profile studies supporting the use of ivermectin, this has resulted in a loss of clinical equipoise that is reflected in low participation in this domain. It is therefore considered that continuation of enrollment to this domain is operationally futile, resulting in the decision to close recruitment and report the results of this domain.

We recommend that continued administration of ivermectin as an allocated intervention as part of the REMAP-CAP trial should be at the discretion of the treating clinician.

---

<sup>1</sup> <https://www.nejm.org/doi/full/10.1056/NEJMoa2115869>

<sup>2</sup> <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362>

<sup>3</sup> <https://jamanetwork.com/journals/jama/fullarticle/2777389>

Updates will be forthcoming when available. We thank you sincerely for your participation in the COVID-19 Antiviral Domain, and REMAP-CAP overall, as we continue to evaluate optimal treatment for CAP and COVID-19.

Sincerely,



Dr Lennie Derde,  
Chair, REMAP-CAP International Trial Steering Committee  
Email: [L.P.G.Derde@umcutrecht.nl](mailto:L.P.G.Derde@umcutrecht.nl)



Professor Yaseen Arabi,  
Chair, REMAP-CAP COVID-19 Antiviral Domain  
Email: [yaseenarabi@yahoo.com](mailto:yaseenarabi@yahoo.com)



Professor Alistair Nichol,  
Deputy Chair, REMAP-CAP COVID-19 Antiviral Domain  
Email: [alistair.nichol@monash.edu](mailto:alistair.nichol@monash.edu)